Discovery of a perinecrotic 60 kDa MDM2 isoform within glioma spheroids and glioblastoma biopsy material

Neuropathology and Applied Neurobiology

Volumn 31, Issue 2, 2005, Pages 191-202

  Bell, Helen S ^a   Whittle, I R ^b   Bader, S A ^c   Wharton, S B ^d  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Glioblastoma; MDM2; Necrosis; p53; Spheroid

Indexed keywords

PROTEIN BAX; PROTEIN MDM2; PROTEIN P53;

ARTICLE; BIOPSY; CARBOXY TERMINAL SEQUENCE; CELL DEATH; CELL KILLING; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; NECROSIS; NERVE BIOPSY; PRIORITY JOURNAL; PROTEIN DOMAIN; SPHEROID CELL; TUMOR LOCALIZATION; WILD TYPE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION; GENES, P53; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; NECROSIS; NUCLEAR PROTEINS; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; PROTO-ONCOGENE PROTEINS P21(RAS); SPHEROIDS, CELLULAR; TRANSFECTION;

EID: 15944399340     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2004.00627.x     Document Type: Article

References (29)

1. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumours of the central nervous system. In World Health Organization International Histological Classification of Tumours 2nd edn. Berlin Heidelberg: Springer-Verlag, 1993
2. Wyllie AH. Apoptosis and carcinogenesis. Eur J Cell Biol 1997; 73: 189-97
3. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-6
4. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000; 275: 8945-51
5. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736-9
6. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Kara E, Vousden KH, Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17: 5001-14
7. Tachibana O, Lampe J, Kleihues P, Ohgaki H. Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme. Acta Neuropathol 1996; 92: 431-4
8. Tohma Y, Gratas C, Van Meir EG, Desbaillets I, Tenan M, Tachibana O, Kleihues P. Ohgaki H. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J Neuropathol Exp Neurol 1998; 57: 239-45
9. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor 1alpha in brain tumors, association with angiogenesis, invasion, and progression. Cancer 2000; 88: 2606-18
10. Wharton SB, McNelis U, Bell HS, Whittle IR. Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model. Neuropathol Appl Neurobiol 2000; 26: 528-35
11. Bell HS, Whittle IR, Walker M, Leaver HA, Wharton SB. The development of necrosis and apoptosis in glioma: experimental findings using spheroid culture systems. Neuropathol Appl Neurobiol 2001; 27: 291-304
12. Mueller-Klieser W. Tumor biology and experimental therapeutics. Crit Rev Oncol Hematol 2000; 36: 123-39
13. Tamaki M, McDonald W, Amberger VR, Moore E. Del Maestro RF. Implantation of C6 astrocytoma spheroid into collagen type I gels: invasive, proliferatlve, and enzymatic characterisations. J Neurosurg 1997; 87: 602-9
14. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y. Diserens AC, Van Meir EG. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999; 9: 469-79
15. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187: 112-26
16. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000; 60: 6788-93
17. Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL, Koeffler HP. Transactivational and DNA binding abilities of endogenous p53 in mutant cell lines. Oncogene 1994; 9: 1899-906
18. Saintigny Y, Rouillard D, Chaput B, Soussi T, Lopez BS. Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint. Oncogene 1999; 18: 3553-63
19. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-9
20. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 300-5
21. LaRue KE, Bradbury EM, Freyer JP. Differential regulation of cyclin-dependent kinase inhibitors in monolayer and spheroid cultures of tumorigenic and nontumorigenic fibroblasts. Cancer Res 1998; 58: 1305-14
22. St Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland JM, Kerbel RS. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol 1998; 142: 557-71
23. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK. Glioblastoma. In Tumours of the Nervous System. Eds P Kleihues, WK Cavanee. Lyon: IARC Press, 2000; 10-21
24. Pochampally R, Fodera B, Chen L, Shao W, Levine EA, Chen J. A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Oncogene 1998; 17: 2629-36
25. Yap DB, Hsieh JK, Lu X. Mdm2 inhibits the apoptotic function of p53 mainly by targeting It for degradation. J Biol Chem 2000; 275: 37296-302
26. Chen J, Wu X, Lin J, Levine AJ. Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 1996; 16: 2445-52
27. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995; 375: 691-4
28. Kowalik TF, DeGregori J, Leone G, Jakoi L, Nevins JR. E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ 1998; 9: 113-8
29. Dilla T, Velasco JA, Medina DL, Gonzalez-Palacios JF, Santisteban P. The MDM2 oncoprotein promotes apoptosis in p53-deficient human medullary thyroid carcinoma cells. Endocrinology 2000; 141: 420-9